Inhaled lipid nanoparticles face several challenges when delivered to the lungs. Here, the authors show “LOOP”-optimized iLNP-HP08LOOP could withstand shear damage generated during nebulization process and be used to develop mRNA-mediated antibody therapy for treating idiopathic pulmonary fibrosis.
- Xin Bai
- Qijing Chen
- Xue-Qing Zhang